Skip to main content
Signal8

Accustem Sciences Inc. (ACUT)

AccuStem Sciences, Inc. operates as a life science firm committed to improving the outlook for individuals battling cancer. Its primary innovation is the StemPrintER technology, an advanced multi-gene prognostic assay designed to predict the likelihood of recurrence for patients with Endocrine receptor-positive /HER2- breast cancer. The company also offers Spare, a related diagnostic tool that expands upon StemPrintER by incorporating two additional clinical markers. AccuStem Sciences, Inc. is based in New York, New York.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Accustem Sciences Inc. logo

Accustem Sciences Inc.

OTC:ACUTHealthcare
-9.23%$0.1180
Mkt Cap$1.9M
EV-
Float8.49M
O/S16.07M
VOL610 sh
$ Vol$74
RVOL0.22×
Inst Own-
SI<0.1%
Net Cash/Sh-
Dilution
Accustem Sciences Inc. logoOTC:ACUT$0.1180-9.23%

Accustem Sciences Inc. (ACUT) dilution facts from SEC filings

Snapshot as of Jun 30, 2026, built from 2 SEC filings.

Shelf registration
None on file in the filings reviewed
At-the-market (ATM) program
No active program in the filings reviewed
Warrants outstanding
1 warrant series recorded as outstanding
Most recent offering
None recorded in the filings reviewed

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro